Targeted disruption of T cell receptor genes using talens
AssigneesSangamo Therapeutics, Inc., Ospedale San Raffaele S.R.L.
InventorsPhilip D. Gregory, Michael C. Holmes, David Paschon, Lei Zhang, Maria Chiara Bonini, Pietro Genovese, Zulma Magnani, Sara Mastaglio, Luigi Naldini
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions for modifying TCR genes, using nucleases (zinc finger nucleases or TAL nucleases) to modify TCR genes.
Claims13
An isolated T-lymphocyte comprising a stably integrated exogenous sequence encoding a T-cell receptor (TCR), wherein at least one endogenous TCR gene within the cell is partially or completely inactivated by a nuclease, wherein the nuclease is a TALEN that binds to a target sequence site in the endogenous TCR gene, wherein said target sequence site is selected from SEQ ID NO:
- 147-153, the TALEN comprising a TAL-effector DNA-binding domain and a cleavage domain, and further wherein the TAL-effector DNA-binding domain comprises a C-terminal truncation as compared to a wild-type TAL-effector DNA-domain.
Dependencies are inferred from the claim text.